Logo image
In vitro susceptibility of recent Chlamydia trachomatis clinical isolates to the CtHtrA inhibitor JO146
Journal article   Open access   Peer reviewed

In vitro susceptibility of recent Chlamydia trachomatis clinical isolates to the CtHtrA inhibitor JO146

Vanissa A Ong, Amba Lawrence, Peter Timms, Lenka A Vodstrcil, Sepehr N Tabrizi, Kenneth W Beagley, John A Allan, Jane S Hocking and Wilhelmina M Huston
Microbes and Infection, Vol.17(11/12), pp.738-744
2015
pdf
PDF - Author's Accepted Version (Open Access)731.73 kBDownloadView
Accepted VersionPDF - Author Accepted Version (Open Access)CC BY-NC-ND V4.0 Open Access
url
https://doi.org/10.1016/j.micinf.2015.09.004View
Published Version

Abstract

chlamydia clinical isolate HtrA inhibitor
The present study aimed to establish if a previously identified Chlamydia trachomatis HtrA (CtHtrA) inhibitor, JO146, is effective against currently circulating clinical isolates to validate if CtHtrA is a clinically relevant target for future therapeutic development. Inhibition of CtHtrA during the middle of the chlamydial replicative cycle until the completion of the cycle resulted in loss of infectious progeny for six unique clinical isolates representing different serovars. This supports the potential for CtHtrA to be a clinically relevant target for development of new therapeutics and suggests the importance of further investigation of JO146 as a lead compound.

Details

Metrics

108 File views/ downloads
1194 Record Views

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types
Domestic collaboration
Web Of Science research areas
Immunology
Infectious Diseases
Microbiology

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Source: InCites

Logo image